Study on Renoprotective effect of cilnidipine and amlodipine along with telmisartan in patients with type-2 diabetes and hypertensio
Not Applicable
- Conditions
- Health Condition 1: I130- Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease
- Registration Number
- CTRI/2024/04/065259
- Lead Sponsor
- Sri Ramaswamy Memorial
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
male and female patients aged 18 years and above diagnosed with hypertension and diabetes mellitus patient with RAS inhibitor such as telmisartan use for more than six months
Exclusion Criteria
patients with severe hypertension greater than 180/95 and significant renal impairment CKD stage 2to5 were not included in the study malignant hypertension heart failure with in six months of cardiovascular events severe diabetes HbA1c above 9 were not included in the study pregnant and lactating women if the patient have low blood pressure or hypotensive below 110 they will be excluded if the proteinuria level also decreases the patient is excluded
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Creatinine level <br/ ><br>Hypertension <br/ ><br>Timepoint: 4th Month <br/ ><br>
- Secondary Outcome Measures
Name Time Method Creatinine level & blood pressureTimepoint: 4th month